Page 281 - Read Online
P. 281

Serra-Aracil et al. Mini-invasive Surg 2019;3:37  I  http://dx.doi.org/10.20517/2574-1225.2019.36                                 Page 5 of 11



























               Figure 1. Flow chart of the study patients. TEM: transanal endoscopic microsurgery; TEO: transanal endoscopic operation


               Table 2. Descriptive epidemiological and preoperative data of patients who underwent TEM
                                                                                            Overall patients
                Variables                                                                    n = 716 (%)
                Epidemiology Age (years) (median-IQR-range)                              71 (IQR 16) (range 31-92)
                          Sex (%)                                             Male       430 (60%)
                                                                              Female     286 (40%)
                          Tumor size (cm) (median-IQR-range)                             4 (IQR 2) (range 0.5-12)
                          Preoperative chemo-radiotherapy                                44 (6.1%)
                          Re-TEM                                                         24 (3.4%)
                          TEM after polypectomy with positive margin resection           48 (6.8%)
                          Distance from anal verge (cm) (median-IQR-range)               7 (IQR 5) (range 1-22)
                          Distance from  tumor proximal margin to anal verge (cm) (median-IQR-range)  11 (IQR 4.5) (range 1-26)
                          Location of the tumor (%)                           Anterior   185 (25.8%)
                                                                              Lateral    318 (44.4%)
                                                                              Posterior  213 (29.7%)
                          Morphology of the lesion (%)                        Flat       169 (23.6)
                                                                              Pedunculated 150 (21.3%)
                                                                              Sessile    329 (47.1%)
                                                                              Ulcerated  54 (7.6%)
                          ASA (%)                                             I          23 (3.2%)
                                                                              II         381 (53.2%)
                                                                              III        254 (35.5%)
                                                                              IV         58 (8.1%)

               TEM: transanal endoscopic surgery; ASA: American Society of Anesthesiology scale; IQR: Interquartile range; Re-TEM: recurrence-TEM

               grade I. Clinically relevant morbidity (Cl-D ≥ II) was reported in 36 (5%) patients with a Comprehensive
                                      [12]
               Complication Index (CCI)  of 0. Fifty-nine (8.2%) patients presented asymptomatic postoperative fever.
               The causes of death in the two (0.3%) patients who were exituswere reported in our previous publication .
                                                                                                        [6]
               The most frequent pathology was adenoma in 422 (58.9%) patients. Full wall resection was achieved in 710
               (99.2%) patients and only 61 (8.6%) patients presented positive margins.

               Table 4 displays the most frequent types of complications related to TEM. In 139/158 (88%) patients, the
               complications were surgical. The most frequent complication was rectal bleeding in 115/716 (16.1%) patients;
               however, the bleeding was Cl-D grade I in 85/115 (73.9%) patients. Fifteen of 115 (13%) patients required
               surgical treatment (a new TEM in all cases). Rectal bleeding was a clinically relevant complication (Cl-D ≥
               II) in 25/716 (3.5%) patients.
   276   277   278   279   280   281   282   283   284   285   286